Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
for HR+/HER2-negative Breast Cancer
10 locations incl. Loma Linda
Sponsor: SynDevRx, Inc.
Sex: All·Age: 18+
Code: NCT05455619·Phase 1, Phase 2·Recruiting